Methods for determining the risk of developing hepatocellular carcinoma from nonalcoholic steatohepatitis

Abstract

Provided is a method for assessing the risk of developing hepatocellular carcinoma from nonalcoholic steatohepatitis (NASH). A method for detecting hepatocytes having a risk of developing hepatocellular carcinoma or detecting tissue that contains said hepatocytes, wherein the method includes detecting the DNA methylation level of target CpG sites in genomic DNA derived from hepatocytes affected with NASH or from tissue that contains said hepatocytes, and detecting hepatocytes having the risk of developing hepatocellular carcinoma or tissue that contains said hepatocytes from the detected DNA methylation level.

Claims

1. A method for detecting hepatocytes or tissues containing hepatocytes at risk of developing hepatocellular carcinoma, comprising: Detecting the DNA methylation level of a target CpG site in genomic DNA derived from a liver cell or a tissue containing the liver cell affected with nonalcoholic steatohepatitis; and Detecting hepatocytes or tissues containing hepatocytes at risk of developing hepatocellular carcinoma based on the detected DNA methylation level; Including, The target CpG site is at least one CpG site selected from the group consisting of CpG sites at chromosomal positions listed in Table 1 and CpG sites located in a region 20 bases upstream to 20 bases downstream from each of the positions; method. 【Table 1】

2. 1. A method for detecting a subject at risk for developing hepatocellular carcinoma, comprising: Detecting the DNA methylation level of a target CpG site in genomic DNA derived from a liver cell or a tissue containing the liver cell of a subject suffering from non-alcoholic steatohepatitis; and Detecting a subject at risk of developing hepatocellular carcinoma from the detected DNA methylation level; Including, The target CpG site is at least one CpG site selected from the group consisting of CpG sites at chromosomal positions listed in Table 2 and CpG sites located in a region 20 bases upstream to 20 bases downstream from each of the positions; method. 【Table 2】

3. A method for obtaining data for detecting hepatocytes or tissues containing the same at risk of developing hepatocellular carcinoma, or subjects at risk of developing hepatocellular carcinoma, comprising the steps of: Detecting the DNA methylation level of a target CpG site in genomic DNA derived from a liver cell or a tissue containing the liver cell of a subject suffering from non-alcoholic steatohepatitis; and Obtaining data on whether or not the hepatocyte or a tissue containing the hepatocyte, or the subject, is at risk of developing hepatocellular carcinoma from the detected DNA methylation level; Including, The target CpG site is at least one CpG site selected from the group consisting of CpG sites at chromosomal positions listed in Table 3 and CpG sites located in a region 20 bases upstream to 20 bases downstream from each of the positions; method. 【Table 3】

4. The method according to any one of claims 1 to 3, wherein the target CpG site is at least one CpG site selected from the group consisting of the CpG sites at positions 130,834,003 on chromosome 10, 114,256,392 on chromosome 2, 28,829,182 on chromosome 6, 144,601,781 on chromosome 8, 144,601,800 on chromosome 8, and 35,700,382 on chromosome 6, and CpG sites located in a region 20 bases upstream to 20 bases downstream from each of said positions.

5. The method according to any one of claims 1 to 4, wherein the detection of the DNA methylation level comprises detecting the DNA methylation level of the target CpG site using the genomic DNA that has been bisulfite-treated.

Images